Who we are
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal/Internal Medicine/Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
Shire was founded in 1986 in the UK. Since then, Shire has grown revenues from $648 million in 2000 to over $12 billion in 2015. The recent combination with Baxalta marks a significant step in our growth.
Shire’s Asia Pacific headquarters in Singapore is the regional hub to 10 locations across Australia/New Zealand, China, Korea, Taiwan/Hong Kong and South East Asia. Singapore is also home to Shire’s first biologics manufacturing site in Asia that officially opened on 7 August 2014. The Woodlands manufacturing facility is one of Shire’s 17 world-class manufacturing sites around the world, and the only facility outside the U.S. and Europe.
Today we have more than 22,000 employees worldwide and offices in over 60 countries. Our products are marketed in more than 100 countries, enabling us to help improve the lives of people around the world whose health is impacted by rare and other highly specialized conditions.